Literature DB >> 10620655

Th1 dominance in HAM/TSP and the optico-spinal form of multiple sclerosis versus Th2 dominance in mite antigen-specific IgE myelitis.

I Horiuchi1, Y Kawano, K Yamasaki, M Minohara, M Furue, T Taniwaki, T Miyazaki, J i Kira.   

Abstract

To clarify the Th1/Th2 balance in spinal cord inflammation, we used ELISA to measure the total and allergen-specific IgE in 69 patients with clinically definite multiple sclerosis (MS), including 24 patients with the optico-spinal form of MS, 45 with HAM/TSP, 30 HTLV-I carriers without HAM/TSP, 40 patients with acute myelitis, 43 with neurodegenerative disorders, and 42 healthy subjects, and flow cytometry to study the intracellular IFNgamma-positive versus IL-4-positive cell ratio (intracellular IFNgamma/IL-4 ratio) in peripheral blood CD4(+) T cells in 40 patients with MS, including 17 patients with the optico-spinal form of MS, 23 with HAM/TSP, 22 with acute myelitis, 23 with neurodegenerative disorders, and 36 healthy subjects. Patients with HAM/TSP showed a significantly higher intracellular IFNgamma/IL-4 ratio, lower IL-4(+)/IFN-gamma(-) cell percentages, lower total IgE level, and lower frequency of cedar pollen-specific IgE than did the controls. The patients with optico-spinal MS showed a significantly higher intracellular IFNgamma/IL-4 ratio and higher IL-4(-)/IFN-gamma(+) cell percentages than the controls even at remission or in the convalescence phase. In contrast, in the patients with acute myelitis, the total serum IgE level and the frequency of mite antigen-specific IgE were significantly elevated in comparison to the controls, while those having mite antigen-specific IgE myelitis showed a significantly lower IFNgamma/IL-4 ratio in the CD4(+) T cells in comparison to the controls. These findings suggest that the Th1 cell response is predominant in HAM/TSP and optico-spinal MS, whereas the Th2 cell response is predominant in mite antigen-specific IgE myelitis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10620655     DOI: 10.1016/s0022-510x(99)00232-4

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  5 in total

Review 1.  Interference with immune function by HTLV-1.

Authors:  P K C Goon; C R M Bangham
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

Review 2.  Neuroimmunity of HTLV-I Infection.

Authors:  Eiji Matsuura; Yoshihisa Yamano; Steven Jacobson
Journal:  J Neuroimmune Pharmacol       Date:  2010-05-02       Impact factor: 4.147

3.  An unusual case of subclinical peripheral neuropathy and cervical spondylosis in atopic myelitis.

Authors:  Alev Leventoglu; Pelin Ozlu; Ferda Ince
Journal:  Case Rep Neurol Med       Date:  2013-10-23

4.  Evaluation of interleukin-32 and cyclooxygenase-2 expression in HAM/TSP patients and HTLV-1 asymptomatic carriers.

Authors:  Niayesh Hatatian; Reza Bosstani; Asadollah Mohammadi; Saeedeh Mehraban; Maryam Mahdifar; Fariba Zemorshidi; Sayed-Hamidreza Mozhgani; Ali Haji Ghadimi; Mohsen Foroughipour; Houshang Rafatpanah
Journal:  Iran J Basic Med Sci       Date:  2021-07       Impact factor: 2.699

5.  NK cells and monocytes modulate primary HTLV-1 infection.

Authors:  Ramona Moles; Sarkis Sarkis; Veronica Galli; Maria Omsland; Maria Artesi; Massimiliano Bissa; Katherine McKinnon; Sophia Brown; Vincent Hahaut; Robyn Washington-Parks; Joshua Welsh; David J Venzon; Anna Gutowska; Melvin N Doster; Matthew W Breed; Kristin E Killoran; Joshua Kramer; Jennifer Jones; Marcin Moniuszko; Anne Van den Broeke; Cynthia A Pise-Masison; Genoveffa Franchini
Journal:  PLoS Pathog       Date:  2022-04-04       Impact factor: 6.823

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.